2. Immunology/Inflammation Protein Tyrosine Kinase/RTK Apoptosis NF-κB
  3. IRAK FLT3 Apoptosis NF-κB MyD88
  4. Emavusertib hydrochloride

Emavusertib hydrochloride  (Synonyms: CA-4948 hydrochloride)

Cat. No.: HY-135317B
Handling Instructions Technical Support

Emavusertib hydrochloride (CA-4948 tosylate) is the hydrochloride salt form of Emavusertib (HY-135317). Emavusertib hydrochloride is an orally active inhibitor for IRAK4 (IC50=57 nM) and FLT3. Emavusertib hydrochloride inhibits NF-κB and MyD88 signaling pathways, reduces the generation of pro-inflammatory cytokines like IL-6 and IL-10, thereby exhibiting anti-inflammatory and anti-proliferative activities against cancer cells, leading to cell apoptosis. Emavusertib hydrochloride exhibits antitumor activity in mouse model.

For research use only. We do not sell to patients.

CAS No. : 2376399-42-5

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other In-stock Forms of Emavusertib hydrochloride:

Other Forms of Emavusertib hydrochloride:

Emavusertib hydrochloride Related Antibodies

Top Publications Citing Use of Products

    Emavusertib hydrochloride purchased from MedChemExpress. Usage Cited in: Leukemia. 2025 Sep;39(9):2163-2173.  [Abstract]

    Cell viability was determined in THP1 and HL60 cells cultured with 10 µM CA-4948 (Emavusertib) or in OCI-AML3 and K562 cultured with 1 µM CA-4948 or vehicle (n = 4) for 14 days and then treated with CC-885 (n = 4).

    Emavusertib hydrochloride purchased from MedChemExpress. Usage Cited in: Leukemia. 2025 Sep;39(9):2163-2173.  [Abstract]

    Immunoblots for c-MYC in the patient-derived AML samples (AML1794, AML1714) cultured with CA-4948 (Emavusertib) (10 µM) or vehicle for 14 days and then treated with CC-885 (50 nM) for 4 h.

    Emavusertib hydrochloride purchased from MedChemExpress. Usage Cited in: Cell Rep. 2025 Sep 24;44(10):116347.  [Abstract]

    Harvested tumor weights by treatment condition (n = 8 per condition).Tumor growth studies demonstrated statistically significant inhibition with both CA-4948 (Emavusertib) (50 mg/kg; oral gavage; once daily) alone and ICB alone.

    Emavusertib hydrochloride purchased from MedChemExpress. Usage Cited in: Cell Rep. 2025 Sep 24;44(10):116347.  [Abstract]

    H&E and trichrome staining of tumors by treatment condition (Emavusertib (50 mg/kg; oral gavage; once daily), ect.) at 10× magnification. The scale bar represents 100 μm.

    Emavusertib hydrochloride purchased from MedChemExpress. Usage Cited in: Blood. 2023 Sep 14;142(11):989-1007.  [Abstract]

    IC50 curves for CA-4948 (Emavusertib) (0.01-10000 nM; 24 h) and PF-06650833 in an assay measuring NF-kB activity upon TLR2 stimulation with PAM3CSK4 in THP1 NF-kB reporter cells.

    Emavusertib hydrochloride purchased from MedChemExpress. Usage Cited in: Blood. 2023 Sep 14;142(11):989-1007.  [Abstract]

    Immunoblots for phospho-IRAK1, total IRAK1, IRAK2, and IRAK4 in MDSL and AML (1714) treated for 24 hours with CA-4948 (Emavusertib) (10 μM). The results showed that treatment with CA-4948 resulted in increased IRAK1 phosphorylation.

    View All IRAK Isoform Specific Products:

    View All Isoforms
    IRAK1 IRAK3 IRAK4

    View All NF-κB Isoform Specific Products:

    View All Isoforms
    NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Emavusertib hydrochloride (CA-4948 tosylate) is the hydrochloride salt form of Emavusertib (HY-135317). Emavusertib hydrochloride is an orally active inhibitor for IRAK4 (IC50=57 nM) and FLT3. Emavusertib hydrochloride inhibits NF-κB and MyD88 signaling pathways, reduces the generation of pro-inflammatory cytokines like IL-6 and IL-10, thereby exhibiting anti-inflammatory and anti-proliferative activities against cancer cells, leading to cell apoptosis. Emavusertib hydrochloride exhibits antitumor activity in mouse model[1][2][3].

    IC50 & Target

    IRAK4

    57 nM (IC50)

    In Vitro

    Emavusertib exhibits >350-fold higher binding affinity for IRAK-4 than that observed for IRAKs 1, 2 and 3[3].
    Emavusertib (10 μM, 72 h) decreases the percentage of proliferating cells and induces a moderate increase in the sub-G0 fraction in marginal zone lymphomas (MZL) cell lines[3].
    Emavusertib (10 μM, 72 h) induces a significant increase in the apoptotic cell population of MZL cells, particularly when combined with Ibrutinib (HY-10997) compared to ibrutinib and emavusertib alone[3].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Emavusertib hydrochloride Related Antibodies
    In Vivo

    Emavusertib (25-150 mg/kg, Orally, once daily, for 14 consecutive days) induces tumor growth inhibition in mice[3].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Mice bearing OCI-LY10 tumors[3]
    Dosage: 25, 50, or 150 mg/kg (once daily), 12.5, 25, or 50 mg/kg (twice daily)
    Administration: Orally, once daily or twice daily, for 14 consecutive days
    Result: Induced tumor growth inhibition. Emavusertib administered as a twice-daily divided dose was equivalent to the corresponding once-daily dose with regards to antitumor activity, i.e., 12.5 mg/kg BID versus 25 mg/kg QD.
    Molecular Weight

    527.96

    Formula

    C24H26ClN7O5
    CAS No.
    SMILES

    O=C(C1=COC(C2=CC=NC(C)=C2)=N1)NC3=C(N4CC[C@H](C4)O)N=C5C(OC(N6CCOCC6)=N5)=C3.Cl
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage

    Please store the product under the recommended conditions in the Certificate of Analysis.
    Purity & Documentation
    References
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Emavusertib hydrochloride Related Classifications

    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass   Concentration   Volume   Molecular Weight *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
    × = ×
    C1   V1   C2   V2
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Emavusertib2376399-42-5CA-4948CA4948CA 4948IRAKFLT3ApoptosisNF-κBMyD88Interleukin-1 receptor associated kinaseIL-1R associated kinaseCluster of differentiation antigen 135CD135Fms like tyrosine kinase 3Nuclear factor-κBNuclear factor-kappaBinflammationMyd88rheumatoidarthritisTollIL-1RlymphomaInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Emavusertib hydrochloride
    Cat. No.:
    HY-135317B
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.